Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: A prospective study i{dotless}n adult and elderly patients with newly diagnosed partial epilepsy

Epilepsy and Behavior

Volumn 13, Issue 1, 2008, Pages 156-161

  Dogan, Ebru Apaydin ^a   Usta, Burcu Ekmekci ^a   Bilgen, Rengin ^a   Senol, Yesim ^a   Aktekin, Berrin ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Elderly; Intracerebral tumors; Monotherapy; Newly diagnosed epilepsy; Oxcarbazepine; Stevens Johnson syndrome; Symptomatic epilepsy

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; OXCARBAZEPINE; SODIUM;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BEHAVIOR; BRAIN TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUID INTAKE; FOCAL EPILEPSY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPONATREMIA; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REMISSION; SEIZURE; SIDE EFFECT; SODIUM BLOOD LEVEL; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; VOMITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; DRUG EVALUATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 46549084628     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.02.001     Document Type: Article

References (28)

1. Paradowski B., and Zagrajek M.M. Epilepsy in middle-aged and elderly people: a three-year observation. Epileptic Disord 7 (2005) 91-95
2. LaRoche S.M. A new look at the second-generation antiepileptic drugs: a decade of experience [review]. Neurologist 13 (2007) 133-139
3. Ramsay R.E., and Pryor F. Epilepsy in the elderly. Neurology 55 Suppl. 1 (2000) 9-14
4. Kutluay E., McCauge K., D'Souza J., and Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 4 (2003) 175-180
5. Sallas W., Hossain M., and D'Souza J. Population pharmacokinetic analysis of oxcarbazepine (Trileptal) in children with epilepsy. Epilepsia 40 Suppl. 7 (1999) S102
6. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., and Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73 1 (2007)
7. Lloyd P., Flesch G., and Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35 Suppl. 3 (1994) 10-13
8. Wellington K., and Goa K.L. Oxcarbazepine: an update of its efficacy in the management of epilepsy [review]. CNS Drugs 15 (2001) 137-163
9. Tudur Smith C., Marson A.G., Chadwick D.W., and Williamson P.R. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 5 8(1) (2007) 34
10. Martinez W., Ingenito A., Blakeslee M., Barkley G.L., McCague K., and D'Souza J. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy Behav 9 (2006) 448-456
11. Pauletto G., Bergonzi P., and for the Triveneto Epilepsy Study Group. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice. Seizure 15 (2006) 150-155
12. Beydoun A, Sfikas N. Oxcarbazepine monotherapy provides effective seizure control for up to four years in patients with refractory partial seizures. Poster presented during the 25th International Epilepsy Congress, Lisbon, Portugal; 12-16 October 2003.
13. Commission on C., and Terminology of the International League Against E. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30 (1989) 389-399
14. Sturm Y, Qian C, Ben-Menachem E. Evidence for sustained effectiveness of up to 4 years oxcarbazepine monotherapy in patients with newly diagnosed epilepsy. Poster presented during the 6th European Congress on Epileptology, Vienna, Austria; May 30-June 3 2004.
15. Mohanraj R., and Brodie M.J. Outcomes in newly diagnosed localization-related epilepsies. Seizure 14 (2005) 318-323
16. Bill P.A., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27 (1997) 195-204
17. Christe W., Kramer G., Vigonius U., et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26 (1997) 451-460
18. Maschio M., Dinapoli L., Zarabia A., and Jandolo B. Issues related to the pharmacological management of patients with brain tumours and epilepsy [review]. Funct Neurol 21 (2006) 15-19
19. Van Breemen M.S., Wilms E.B., and Vecht C.J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6 (2007) 421-430
20. Saetre E., Perucca E., Isojärvi J., and Gjerstad L. An international multicenter randomized double blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 48 (2007) 1292-1302
21. Belcastro V., Costa C., Galletti F., Pisani F., Calabrasi P., and Parnetti L. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol 14 (2007) 1176-1178
22. Zaccara G., Messori A., Cinconta M., and Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies [review]. Acta Neurol Scand 114 (2006) 157-168
23. Glauser T., Ben-Menachem E., Bourgeois B., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47 (2006) 1094-1120
24. Schmidt D., Arroyo S., Baulac M., et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus review. Acta Neurol Scand 104 (2001) 167-170
25. Arif H., Buchsbaum R., Weintraub D., et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68 (2007) 1701-1709
26. Alvestad S., Lydersen S., and Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 48 (2007) 1360-1365
27. Knuden J.F., Flowers C.M., Kortepeter C., and Awaad Y. Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review. Pediatr Neurol 37 (2007) 134-137
28. Ryu D.R., Song P.S., Lee J.Y., et al. A case of Stevens-Johnson syndrome caused by oxcarbazepine [abstract]. Kor J Med 70 (2006) 586-590